Weiguang Wang

Prof. Dr. Weiguang Wang

Faculty of Science & Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
NYN C Yip
N C Yip
IFI S Fombon
I S Fombon
PLP Liu
P Liu
SBS Brown
S Brown
VKV Kannappan
V Kannappan
WWWeiguang Wang
Weiguang Wang
Previous studies indicate that disulfiram (DS), an anti-alcoholism drug, is cytotoxic to cancer cell lines and reverses anticancer drug resistance. Cancer stem cells (CSCs) are the major cause of chemoresistance leading to the failure of cancer chemotherapy. This study intended to examine the effect of DS on breast cancer stem cells (BCSCs). The effect of DS on BC cell lines and BCSCs was determined by MTT, western blot, CSCs culture and CSCs marker analysis. Disulfiram was highly toxic to BC cell lines in vitro in a copper (Cu)-dependent manner. In Cu-containing medium (1 μM), the IC50 concentrations of DS in BC cell lines were 200–500 nM. Disulfiram/copper significantly enhanced (3.7–15.5-fold) cytotoxicity of paclitaxel (PAC). Combination index isobologram analysis demonstrated a synergistic effect between DS/Cu and PAC. The increased Bax and Bcl2 protein expression ratio indicated that intrinsic apoptotic pathway may be involved in DS/Cu-induced apoptosis. Clonogenic assay showed DS/Cu-inhibited clonogenicity of BC cells. Mammosphere formation and the ALDH1+VE and CD24Low/CD44High CSCs population in mammospheres were significantly inhibited by exposure to DS/Cu for 24 h. Disulfiram/copper induced reactive oxygen species (ROS) generation and activated its downstream apoptosis-related cJun N-terminal kinase and p38 MAPK pathways. Meanwhile, the constitutive NFκB activity in BC cell lines was inhibited by DS/Cu. Disulfiram/copper inhibited BCSCs and enhanced cytotoxicity of PAC in BC cell lines. This may be caused by simultaneous induction of ROS and inhibition of NFκB.

2 October 2012 in British Journal of Cancer
Verified
Journal Article
Open access
PLP Liu
P Liu
SBS Brown
S Brown
TGT Goktug
T Goktug
PCP Channathodiyil
P Channathodiyil
VKV Kannappan
V Kannappan
WWWeiguang Wang
Weiguang Wang
Background: Methods: Results: Conclusion:

21 January 2003 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
WWWeiguang Wang
Weiguang Wang
HMHoward L. McLeod
Howard L. McLeod
JCJames Cassidy
James Cassidy
5‐Fluorouracil (5‐FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours. Resistance of cancer cells to 5‐FU is considered the major obstacle for successful chemotherapy. NF‐κB is a transcription factor. Cancer cells with high NF‐κB nuclear activity demonstrate robust chemo‐ and radio‐resistance. We demonstrated that nuclear NF‐κB activity in CRC cell lines, DLD‐1 and RKOWT, was significantly induced by 5‐FU in a concentration‐ and time‐dependent manner. 5‐FU induced IκBα degradation and promoted both NF‐κB nuclear translocation and its DNA binding activity. 5‐FU treatment did not influence the activities of AP‐1, AP‐2, Oct‐1, SP‐1, CRE‐B and TFIID. Disulfiram (DS), a clinically used anti‐alcoholism drug, strongly inhibited constitutive and 5‐FU‐induced NF‐κB activity in a dose‐dependent manner. DS inhibited both NF‐κB nuclear translocation and DNA binding activity but had no effect on 5‐FU‐induced IκBα degradation. Used in combination, DS significantly enhanced the apoptotic effect of 5‐FU on DLD‐1 and RKOWT cell lines and synergistically potentiated the cytotoxicity of 5‐FU to both cell lines. DS also effectively abolished 5‐FU chemoresistance in a 5‐FU resistant cell line H6305‐FU in vitro. As DS has extensive preclinical and clinical experience, translating its anticancer usage from in vitro study to clinical trials is relatively straightforward.

5 September 2013 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
PLP Liu
P Liu
IKI S Kumar
I S Kumar
SBS Brown
S Brown
VKV Kannappan
V Kannappan
PTP E Tawari
P E Tawari
WWWeiguang Wang
Weiguang Wang
Triple-negative breast cancer (TNBC) has significantly worse prognosis. Acquired chemoresistance remains the major cause of therapeutic failure of TNBC. In clinic, the relapsed TNBC is commonly pan-resistant to various drugs with completely different resistant mechanisms. Investigation of the mechanisms and development of new drugs to target pan-chemoresistance will potentially improve the therapeutic outcomes of TNBC patients. In this study, 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT), combination index (CI)–isobologram, western blot, ALDEFLUOR analysis, clonogenic assay and immunocytochemistry were used. The chemoresistant MDA-MB-231PAC10 cells are highly cross-resistant to paclitaxel (PAC), cisplatin (CDDP), docetaxel and doxorubicin. The MDA-MB-231PAC10 cells are quiescent with significantly longer doubling time (64.9 vs 31.7 h). This may be caused by high expression of p21Waf1. The MDA-MB-231PAC10 cells express high aldehyde dehydrogenase (ALDH) activity and a panel of embryonic stem cell-related proteins, for example, Oct4, Sox2, Nanog and nuclealisation of HIF2α and NF-κBp65. We have previously reported that disulfiram (DS), an antialcoholism drug, targets cancer stem cells (CSCs) and enhances cytotoxicity of anticancer drugs. Disulfiram abolished CSC characters and completely reversed PAC and CDDP resistance in MDA-MB-231PAC10 cells. Cancer stem cells may be responsible for acquired pan-chemoresistance. As a drug used in clinic, DS may be repurposed as a CSC inhibitor to reverse the acquired pan-chemoresistance.

13 April 2013 in Oncotarget
Verified
Journal Article
Open access
PDF file
RKRICHARD E. KAST
RICHARD E. KAST
JBJohn A. Boockvar
John A. Boockvar
ABAnsgar Brüning
Ansgar Brüning
Francesco CappelloFrancesco Cappello
Francesco Cappello
Wen-Wei ChangWen-Wei Chang
Wen-Wei Chang
MHMarc-Eric Halatsch
Marc-Eric Halatsch
To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria: a) were pharmacologically well characterized, b) had low likelihood of adding to patient side effect burden, c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth. We found nine drugs meeting these criteria and propose adding them to continuous low dose temozolomide, a currently accepted treatment for relapsed glioblastoma, in patients with recurrent disease after primary treatment with the Stupp Protocol. The nine adjuvant drug regimen, Coordinated Undermining of Survival Paths, CUSP9, then are aprepitant, artesunate, auranofin, captopril, copper gluconate, disulfiram, ketoconazole, nelfinavir, sertraline, to be added to continuous low dose temozolomide. We discuss each drug in turn and the specific rationale for use- how each drug is expected to retard glioblastoma growth and undermine glioblastoma’s compensatory mechanisms engaged during temozolomide treatment. The risks of pharmacological interactions and why we believe this drug mix will increase both quality of life and overall survival are reviewed.

17 September 2021 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
VKVinodh Kannappan
Vinodh Kannappan
MAMisha Ali
Misha Ali
BSBenjamin Small
Benjamin Small
GRGowtham Rajendran
Gowtham Rajendran
SESalena Elzhenni
Salena Elzhenni
Q. Ping DouQ. Ping Dou
Q. Ping Dou
Copper (Cu) plays a pivotal role in cancer progression by acting as a co-factor that regulates the activity of many enzymes and structural proteins in cancer cells. Therefore, Cu-based complexes have been investigated as novel anticancer metallodrugs and are considered as a complementary strategy for currently used platinum agents with undesirable general toxicity. Due to the high failure rate and increased cost of new drugs, there is a global drive towards the repositioning of known drugs for cancer treatment in recent years. Disulfiram (DSF) is a first-line antialcoholism drug used in clinics for more than 65 yr. In combination with Cu, it has shown great potential as an anticancer drug by targeting a wide range of cancers. The reaction between DSF and Cu ions forms a copper diethyldithiocarbamate complex (Cu(DDC)2also known as CuET) which is the active, potent anticancer ingredient through inhibition of NF-κB and ubiquitin-proteasome system as well as alteration of the intracellular reactive oxygen species (ROS). Importantly, DSF/Cu inhibits several molecular targets related to drug resistance, stemness, angiogenesis and metastasis and is thus considered as a novel strategy for overcoming tumour recurrence and relapse in patients. Despite its excellent anticancer efficacy, DSF has proven unsuccessful in several cancer clinical trials. This is likely due to the poor stability, rapid metabolism and/or short plasma half-life of the currently used oral version of DSF and the inability to form Cu(DDC)2at relevant concentrations in tumour tissues. Here, we summarize the scientific rationale, molecular targets, and mechanisms of action of DSF/Cu in cancer cells and the outcomes of oral DSF ± Cu in cancer clinical trials. We will focus on the novel insights on harnessing the immune system and hypoxic microenvironment using DSF/Cu complex and discuss the emerging delivery strategies that can overcome the shortcomings of DSF-based anticancer therapies and provide opportunities for translation of DSF/Cu or its Cu(DDC)2complex into cancer therapeutics.